Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type i GnRH receptor

International Journal of Oncology

Volumn 46, Issue 1, 2015, Pages 243-253

  Montagnani Marelli, Marina ^a   Manea, Marilena ^b   Moretti, Roberta M ^a   Marzagalli, Monica ^a   Limonta, Patrizia ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

Castrationresistant prostate cancer; Daunorubicin; Daunorubicin GnRH III bioconjugates; GnRH III; Gonadotropin releasing hormone receptor

Indexed keywords

ANTINEOPLASTIC AGENT; DAUNORUBICIN; GNRHR PROTEIN, HUMAN; GONADORELIN; GONADORELIN RECEPTOR; GONADOTROPIN-RELEASING HORMONE-III; OXIME; PYROGLUTAMIC ACID;

ANALOGS AND DERIVATIVES; APOPTOSIS; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; MALE; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; OXIMES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PYRROLIDONECARBOXYLIC ACID; RECEPTORS, LHRH; TUMOR CELLS, CULTURED;

EID: 84917706541     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2730     Document Type: Article

References (40)

1. Schally AV, Arimura A, Baba Y, Nair RM, Matsuo H, Redding TW and Debeljuk L: Isolation and properties of the FSH and LH-releasing hormone. Biochem Biophys Res Commun 43: 393-399, 1971.
2. Kakar SS, Malik MT, Winters SJ and Mazhawidza W: Gonadotropin-releasing hormone receptors: structure, expression, and signaling transduction. Vitam Horm 69: 151-207, 2004.
3. Millar RP: GnRHs and GnRH receptors. Anim Reprod Sci 88: 5-28, 2005.
4. Emons G and Schally AV: The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod 9: 1364-1379, 1994.
5. Labrie F, Belanger A, Luu-The V, et al: Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 26: 361-379, 2005.
6. Imai A and Tamaya T: GnRH receptor and apoptotic signaling. Vitam Horm 59: 1-33, 2000.
7. Grundker C, Gunthert AR, Westphalen S and Emons G: Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 146: 1-14, 2002.
8. Montagnani Marelli M, Moretti RM, Januszkiewicz-Caulier J, Motta M and Limonta P: Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients? Curr Cancer Drug Targets 6: 257-269, 2006.
9. Limonta P, Montagnani Marelli M, Mai S, Motta M, Martini L and Moretti RM: GnRH receptors in cancer: from cell biology to novel targeted therapeutic strategies. Endocr Rev 33: 784-811, 2012.
10. Limonta P and Manea M: Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies. Cancer Treat Rev 39: 647-663, 2013.
11. Engel J, Emons G, Pinski J and Schally AV: AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors. Expert Opin Investig Drugs 21: 891-899, 2012.
12. Kovacs M, Seprodi J, Koppan M, Horvath JE, Vincze B, Teplan I and Flerko B: Lamprey gonadotropin hormone-releasing hormone-III has no selective follicle-stimulating hormonereleasing effect in rats. J Neuroendocrinol 14: 647-655, 2002.
13. Szabo I, Manea M, Orban E, et al: Development of an oxime bond containing daunorubicin-gonadotropin-releasing hormone-III conjugate as a potential anticancer drug. Bioconjug Chem 20: 656-665, 2009.
14. Manea M, Leurs U, Orban E, et al: Enhanced enzymatic stability and antitumor activity of daunorubicin-GnRH-III bioconjugates modified in position 4. Bioconjug Chem 22: 1320-1329, 2011.
15. Orban E, Mezo G, Schlage P, et al: In vitro degradation and antitumor activity of oxime bond-linked daunorubicin-GnRH-III bioconjugates and DNA-binding properties of daunorubicinamino acid metabolites. Amino Acids 41: 469-483, 2011.
16. Schlage P, Mezo G, Orban E, Bosze S and Manea M: Anthracycline-GnRH derivative bioconjugates with different linkages: synthesis, in vitro drug release and cytostatic effect. J Control Release 156: 170-178, 2011.
17. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
18. Akaza H: Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci 102: 51-56, 2011.
19. Fitzpatrick JM: Management of castration-resistant prostate cancer: a call to urologists. BJU Int 110: 772-774, 2012.
20. Lee DJ, Cha EK, Dubin JM, et al: Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). BJU Int 109: 968-985, 2012.
21. Dondi D, Limonta P, Moretti RM, Montagnani Marelli M, Garattini E and Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 54: 4091-4095, 1994.
22. Dondi D, Moretti RM, Montagnani Marelli M, et al: Growthinhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgenindependent prostate cancer cell line in nude mice. Int J Cancer 76: 506-511, 1998.
23. Limonta P, Moretti RM, Montagnani Marelli M, Dondi D, Parenti M and Motta M: The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 140: 5250-5256, 1999.
24. Montagnani Marelli M, Moretti RM, Mai S, Procacci P and Limonta P: Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. Int J Oncol 30: 261-271, 2007.
25. Montagnani Marelli M, Moretti RM, Mai S, Januszkiewicz- Caulier J, Motta M and Limonta P: Type I gonadotropin-releasing hormone receptor mediates the antiproliferative effects of GnRH-II on prostate cancer cells. J Clin Endocrinol Metab 94: 1761-1767, 2009.
26. Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN and Leung HY: Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. J Pathol 206: 205-213, 2005.
27. Liu SV, Schally AV, Hawes D, et al: Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists. Clin Cancer Res 16: 4675-4680, 2010.
28. Palyi I, Vincze B, Lovas S, et al: Gonadotropin-releasing hormone analogue conjugates with strong selective antitumor activity. Proc Natl Acad Sci USA 96: 2361-2366, 1999.
29. Hong SW, Shin JS, Moon JH, et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype. Apoptosis 19: 895-904, 2014.
30. Engel JB, Schally AV, Buchholz S, Seitz S, Emons G and Ortmann O: Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormonereleasing hormone (LHRH). Arch Gynecol Obstet 286: 437-442, 2012.
31. Emons G, Gorchev G, Harter P, et al: Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5). Int J Gynecol Cancer 24: 260-265, 2014.
32. Szepeshazi K, Schally AV, Keller G, et al: Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS-108]. Oncotarget 3: 686-699, 2012.
33. Jaszberenyi M, Schally AV, Block NL, Nadji M, Vidaurre I, Szalontay L and Rick FG: Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone. Oncotarget 4: 422-432, 2013.
34. Szepeshazi K, Schally AV, Block NL, et al: Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108. Oncotarget 4: 751-760, 2013.
35. Manea M, Tovari J, Tejeda M, Schulcz A, Kapuvari B, Vincze B and Mezo G: In-vivo antitumour effect of daunorubicin- GnRH-III derivative conjugates on colon carcinoma-bearing mice. Anticancer Drugs 23: 90-97, 2012.
36. Letsch M, Schally AV, Szepeshazi K, Halmos G and Nagy A: Preclinical evaluation of targeted cytotoxic luteinizing hormonereleasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers. Clin Cancer Res 9: 4505-4513, 2003.
37. Karampelas T, Argyros O, Sayyad N, et al: GnRH-gemcitabine conjugates for the treatment of androgen-independent prostate cancer: pharmacokinetic enhancements combined with targeted drug delivery. Bioconjug Chem 25: 813-823, 2014.
38. Hegedüs R, Manea M, Orbán E, et al: Enhanced cellular uptake and in vitro antitumor activity of short-chain fatty acid acylated daunorubicin-GnRH-III bioconjugates. Eur J Med Chem 56: 155-165, 2012.
39. Cheng CK and Leung PC: Molecular biology of gonadotropinreleasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 26: 283-306, 2005.
40. Leurs U, Lajko E, Mezo G, et al: GnRH-III based multifunctional drug delivery systems containing daunorubicin and methotrexate. Eur J Med Chem 52: 173-183, 2012.